MACI

MACI. Matrix-induced autologous chondrocyte implantation is an advanced, two-stage surgical technique for repairing articular cartilage defects in the knee. It involves harvesting a patient's own cartilage cells, expanding them in a laboratory on a collagen membrane, and then implanting that cell-seeded scaffold into the prepared defect. This procedure is indicated for symptomatic, full-thickness cartilage lesions and represents a significant evolution from earlier autologous chondrocyte implantation techniques.

Overview

MACI is classified as a third-generation autologous chondrocyte implantation method, designed to improve upon the limitations of earlier procedures like ACI and matrix-assisted chondrocyte implantation. The core innovation is the use of a biodegradable type I/III collagen membrane as a carrier for the cultured chondrocytes, which eliminates the need for a periosteal patch and associated suturing. This technique is primarily utilized for treating focal chondral defects and osteochondritis dissecans in the tibia and femur, with the goal of restoring a durable hyaline-like cartilage surface. Its development was pioneered by researchers and companies like Genzyme, now part of Sanofi, following foundational work at institutions such as the University of Gothenburg.

Medical Procedure

The procedure is performed in two distinct stages. First, during an initial arthroscopy, a small biopsy of healthy articular cartilage is harvested, typically from a non-weight-bearing area of the intercondylar notch or the superior ridge of the medial femoral condyle. These chondrocytes are then sent to a specialized laboratory, such as those operated by Vericel Corporation, where they are enzymatically isolated and cultured for several weeks on the proprietary collagen membrane. In the second, open-knee surgery, the defect is debrided to stable cartilage margins, the MACI implant is trimmed to size, and it is secured into the defect using a combination of fibrin glue and limited suturing, allowing for a stable, sutureless fixation in most cases.

Clinical Applications

MACI is clinically indicated for the repair of symptomatic, single or multiple, full-thickness cartilage lesions of the knee in adults, with defect sizes typically ranging from 2 to 10 square centimeters. It is often considered after the failure of first-line interventions like debridement, microfracture surgery, or osteochondral autograft transfer system procedures. Key patient selection criteria include a focal, contained defect with intact subchondral bone, normal knee alignment, and stable cruciate ligaments. It is generally not recommended for patients with advanced osteoarthritis, inflammatory arthritis such as rheumatoid arthritis, or significant meniscus deficiency that cannot be addressed concurrently.

Outcomes and Efficacy

Long-term clinical studies, including the pivotal SUMMIT trial conducted under the oversight of the U.S. Food and Drug Administration, have demonstrated that MACI provides statistically significant and clinically meaningful improvements in knee injury and osteoarthritis outcome score and other patient-reported outcomes compared to microfracture surgery. Magnetic resonance imaging evaluations often show good defect fill and integration with the surrounding native cartilage. While the regenerated tissue frequently exhibits a mix of hyaline cartilage and fibrocartilage, it is generally biomechanically superior to the fibrocartilage produced by microfracture. Potential complications can include graft hypertrophy, delamination, arthrofibrosis, and the general risks associated with any major knee surgery.

Development and History

The scientific foundation for MACI was built upon the pioneering first-generation ACI procedure developed by Mats Brittberg and colleagues in Sweden during the late 1980s. Seeking to improve technical ease and outcomes, second-generation techniques that used collagen covers evolved, leading directly to the third-generation MACI concept. The specific MACI product was developed and commercialized by Genzyme Tissue Repair, receiving Conformité Européenne mark approval in Europe in the late 1990s. After extensive clinical trials, it gained premarket approval from the FDA in 2016, representing a major milestone in the field of orthopedic surgery and cartilage repair.

Category:Orthopedic surgical procedures Category:Knee surgery